Par Drugs And Chemicals Limited

NSE: PAR · Unclassified

₹109.00-2.50%06 Nov 2026

Ask the data

Instant answers about Par Drugs And Chemicals Limited — computed from its filings, no language model

Market cap₹134 cr

Current price₹109.00

High / Low₹168 / ₹79

P/E10.3

P/B1.12

Book value₹97.0

ROE10.9%

ROCE14.4%

Debt / equity0.00

Dividend yield—

EPS (TTM)₹10.56

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY22	FY23	FY24	FY25	FY26
Revenue	75.1	95.8	95.6	101.0	103.7
EBITDA	16.2	18.2	22.8	19.5	17.1
Operating margin	21.6%	19.0%	23.9%	19.3%	16.5%
Interest	0.5	0.1	0.1	0.1	0.1
Depreciation	3.3	3.2	3.4	3.6	3.7
Profit before tax	12.7	15.1	19.5	17.9	17.3
Tax	3.5	3.8	5.0	4.6	4.2
Net profit	0.0	11.3	14.5	13.4	13.1
EPS ₹	7.49	9.21	11.78	10.86	10.65
Operating cash flow	7.6	13.4	20.2	16.2	16.4
Capex	3.2	7.6	6.1	1.2	2.0
Dividend paid	1.5	0.0	0.0	0.0	0.0
Total assets	—	88.9	101.6	119.4	129.2
Equity	—	71.2	85.6	99.0	112.0

Quarterly performance

last 20 quarters · ₹ crore

showing latest 8 of 20 periods

	SEP '21	DEC '21	MAR '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	19.6	16.9	22.1	24.8	22.9	24.5	22.9	25.9	24.0	22.8	22.6	34.7	21.4	22.3	26.1	28.7	29.3	19.6	31.3	27.4
Operating profit	4.0	3.6	4.5	5.9	3.2	5.4	4.1	7.4	5.2	6.1	4.2	11.4	1.4	2.4	3.6	6.1	6.1	1.4	6.4	4.5
Operating margin	20.6%	21.0%	20.5%	23.8%	14.1%	22.0%	18.0%	28.4%	21.8%	26.7%	18.8%	32.9%	6.7%	10.9%	13.7%	21.2%	20.7%	7.3%	20.4%	16.4%
Other income	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.2	-0.1	0.1	1.0	0.3	0.8	1.8	0.5	1.3	0.4	0.9	0.0
Interest	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
Depreciation	0.8	0.8	0.9	0.9	0.7	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	0.9
Profit before tax	3.0	2.7	3.6	5.0	2.5	4.5	3.3	6.5	4.6	5.1	3.4	11.5	0.8	2.3	4.5	5.5	6.4	0.8	6.3	3.5
Tax	0.8	0.6	1.2	1.2	0.6	1.1	0.8	1.6	1.1	1.4	0.8	2.9	0.2	0.6	1.1	1.4	1.6	-0.0	1.6	0.9
Net profit	0.0	0.0	0.0	3.7	1.9	3.5	2.5	4.9	3.4	3.7	2.5	8.6	0.6	1.6	3.3	4.1	4.8	0.8	4.7	2.6
EPS ₹	1.80	1.72	1.97	3.03	1.52	2.80	2.01	3.97	2.78	3.02	2.06	6.99	0.47	1.34	2.70	3.36	3.90	0.69	3.83	2.14
Revenue YoY	—	—	—	26.7%	35.5%	10.9%	—	4.3%	4.7%	-6.8%	-1.4%	33.9%	-10.9%	-2.1%	15.2%	-17.3%	37.2%	-12.2%	20.1%	-4.3%
Profit YoY	—	—	—	—	—	—	—	31.1%	82.9%	7.8%	2.4%	75.9%	-83.0%	-55.6%	31.6%	-52.0%	727.6%	-48.5%	41.4%	-36.3%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 14 periods

	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	16.2%	16.1%	18.1%	16.9%	17.0%	18.9%	15.9%	13.5%	14.3%	9.1%	13.1%	11.7%	12.9%	10.9%
ROCE	21.7%	21.6%	24.2%	22.9%	23.0%	25.5%	21.6%	18.2%	19.3%	12.4%	17.7%	15.6%	17.2%	14.4%
Net margin	12.1%	13.2%	14.6%	15.2%	15.3%	17.6%	15.2%	13.2%	13.6%	9.8%	13.1%	12.6%	13.3%	12.1%
EBITDA margin	19.6%	20.9%	22.7%	23.8%	24.0%	25.9%	22.8%	19.3%	18.0%	13.7%	17.0%	16.5%	18.3%	17.1%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	140.27	154.45	190.50	163.67	164.33	205.58	189.64	225.00	238.75	131.80	188.50	145.17	160.58	191.44
Asset turnover	1.07	1.01	1.02	0.94	0.94	0.90	0.88	0.85	0.87	0.77	0.83	0.80	0.84	0.78

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	12.3	12.3	12.3	12.3	12.3	12.3	12.3	12.3	12.3
Other equity / reserves	53.6	58.9	66.3	73.3	84.5	86.7	94.1	99.7	107.0
Total equity	65.9	71.2	78.6	85.6	96.8	99.0	106.4	112.0	119.3
Borrowings	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Current liabilities	15.0	14.0	13.3	12.4	15.3	16.6	17.5	13.7	16.1
Non-current liabilities	4.0	3.6	3.8	3.5	3.5	3.9	3.6	3.5	3.3
Total assets	84.9	88.9	95.7	101.6	115.7	119.4	127.5	129.2	138.7
Property, plant & equipment	33.1	38.5	40.0	41.3	40.1	38.9	37.7	36.4	36.3
Capital work-in-progress	2.4	0.2	1.0	0.0	0.0	0.0	0.1	0.7	0.0
Investments	0.0	0.0	0.0	0.0	25.9	25.1	26.7	27.1	34.7
Inventories	4.5	5.4	4.2	4.2	4.9	6.1	5.3	5.4	5.0
Receivables	22.2	17.0	17.1	13.7	23.0	16.7	17.6	12.0	22.9
Cash & equivalents	19.4	22.2	29.9	36.6	18.8	27.6	33.9	41.8	36.4

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	7.6	13.4	20.2	16.2	16.4
Cash from investing	-3.0	-7.3	-5.8	-25.2	-2.2
Cash from financing	-9.6	0.0	0.0	0.0	0.0
Capex	3.2	7.6	6.1	1.2	2.0
Free cash flow	4.4	5.7	14.2	14.9	14.5
Dividends paid	1.5	0.0	0.0	0.0	0.0

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹36.3 cr26%

Investments

₹34.7 cr25%

Inventories

₹5.0 cr4%

Receivables

₹22.9 cr17%

Cash & equivalents

₹36.4 cr26%

Other assets

₹3.4 cr2%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Par Drugs And Chemicals Limited	134	109.00	10.3	1.12	10.9%

StoxGud checklist: Bullish setup · 7/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-13.0%

6 months+16.1%

1 year+7.9%

3Y CAGR-20.9%

5Y CAGR-16.2%

10Y CAGR—

50-day avg₹123.30

200-day avg₹100.32

RSI (14)49

FAQs

What is the share price of Par Drugs And Chemicals Limited?

Par Drugs And Chemicals Limited (PAR) closed at ₹109.00 on NSE on 06 Nov 2026.

What is the market cap of Par Drugs And Chemicals Limited?

₹134 crore at the latest close.

What is the P/E ratio of Par Drugs And Chemicals Limited?

10.3, on trailing-twelve-month earnings from its filings.

How fast is Par Drugs And Chemicals Limited growing?

Par Drugs And Chemicals Limited: revenue has compounded at 2.7% a year over three years; net profit at 5.0% a year. Latest-quarter revenue is down 4.3% year on year, profit down 36.3%.

How profitable is Par Drugs And Chemicals Limited?

On a trailing-twelve-month basis return on equity is 10.9%, return on capital employed 14.4%, operating margin 17.1%, net margin 12.1%.

How much debt does Par Drugs And Chemicals Limited have?

Par Drugs And Chemicals Limited is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹36 cr (balance sheet of 2026-09-30). Operating profit covers interest 191.4 times.

Financials parsed from Par Drugs And Chemicals Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Quarterly from SEP '21, annual from FY22, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.